title: Developmental toxicity studies of lumefantrine and artemether in rats and rabbits.
abstract: The combination of artemether plus lumefantrine is a type of artemisinin-based combination therapy (ACT) recommended by the World Health Organization for uncomplicated falciparum malaria except in the first trimester of pregnancy. The first trimester restriction was based on the marked embryotoxicity in animals (including embryo death and cardiac and skeletal malformations) of artemisinins such as artesunate, dihydroartemisinin, and artemether. Before recommending ACTs for use in the first trimester, the World Health Organization has requested that all information relevant to the assessment of risk of ACTs to the embryo be made available to the public. This report describes the results of embryo-fetal development studies of artemether alone, lumefantrine alone, and the combination in rats and rabbits as well as toxicokinetic studies of lumefantrine in pregnant rabbits. The developmental no-effect levels for lumefantrine were 300 mg/kg/day in rats (based on a 25% decrease in litter size at 1000 mg/kg/day) and 1000 mg/kg/day in rabbits. The calculated safety margins based on human equivalent dose and plasma Cmaxand AUC values were in the range of 2.5- to 17-fold. The developmental no-effect levels for artemether were 3 mg/kg/day in rats and 25 mg/kg/day in rabbits. Lumefantrine caused no teratogenicity and was not a potent embryotoxin in rats and rabbits. Expected artemisinin-like findings were seen with artemether alone and with artemether/lumefantrine combined except that no malformations were observed. There were no findings in pregnant rats and rabbits that would cause increased concern for the use of artemether-lumefantrine in the first trimester compared to other ACTs.
authors.affiliation: Artemis Pharmaceutical Research, Jacksonville, FL, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Clark
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Maureen
authors.initials: M
authors.lastname: Youreneff
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Anthony M
authors.initials: AM
authors.lastname: DeLise
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000633:toxicity*; D000077549:Artemether; D037621:Artemisinins / Q000633:toxicity*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D047108:Embryonic Development / Q000187:drug effects; D004983:Ethanolamines / Q000633:toxicity*; D005260:Female; D047109:Fetal Development / Q000187:drug effects; D005449:Fluorenes / Q000633:toxicity*; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D018675:Toxicity Tests; D066007:Toxicokinetics
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004983:Ethanolamines; D005449:Fluorenes; D000077549:Artemether; D000078102:Lumefantrine
keywords: artemether; embryo-fetal development; embryotoxicity; lumefantrine; malaria; rabbit; rat